title: [Filgrastim in refractory Crohn's disease with an intra-abdominal abscess].
abstract: The application of recombinant human granulocyte colony-stimulating factor (filgrastim) seems to be a safe, well tolerated and potentially effective therapy for active Crohn's disease. We report the case of an adolescent boy with Crohn's disease and intra-abdominal abscess associated who had a significant response to treatment with recombinant human granulocyte colony-stimulating factor after all standard treatments had failed.
authors.affiliation: Servicio de Gastroenterología, Hospital Ramón y Cajal, Madrid, España. rivernautaes@yahoo.es
authors.forename: Miguel
authors.initials: M
authors.lastname: Rivero Fernández
authors.forename: Antonio
authors.initials: A
authors.lastname: López San Román
authors.forename: Elena
authors.initials: E
authors.lastname: Garrido Gómez
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Rodríguez Gandía
authors.forename: Luis
authors.initials: L
authors.lastname: Ruiz Del Arbol Olmos
authors.forename: José María
authors.initials: JM
authors.lastname: Milicua Salamero
mesh_terms: D018784:Abdominal Abscess / Q000209:etiology*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002454:Cell Differentiation; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D016207:Cytokines / Q000096:biosynthesis; D004351:Drug Resistance; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008264:Macrophages / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009504:Neutrophils / Q000187:drug effects; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D016207:Cytokines; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D016179:Granulocyte Colony-Stimulating Factor; D000069285:Infliximab; D001379:Azathioprine; D000069585:Filgrastim; D011241:Prednisone; D008727:Methotrexate